aTyr Pharma (FRA:471A) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:471A aTyr Pharma Inc FRA:471A
21 GF Score
Price €0.38
GF Value €0.35
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is aTyr Pharma Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:471A
21GF Score
aTyr Pharma Inc FRA:471A
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is aTyr Pharma (FRA:471A) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of €0.38 is trading 8.6% above its estimated GF Value™ of €0.35. GuruFocus considers aTyr Pharma to be Fairly Valued.

Key valuation signals for FRA:471A:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.35 vs. price of €0.38 (8.6% above fair value)
  • GF Score™: 21/100 with 3 warning signs

No single metric tells the full story. See the FRA:471A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges ATYR:USA471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
21GF Score

Get the complete analysis for FRA:471A

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€0.35
GF Value